Gnana Prakash Balasubramanian

ORCID: 0000-0003-3901-1244
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • FOXO transcription factor regulation
  • Childhood Cancer Survivors' Quality of Life
  • Radiation Therapy and Dosimetry
  • Renal and related cancers
  • Ferroptosis and cancer prognosis
  • Testicular diseases and treatments
  • Glioma Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Neuroblastoma Research and Treatments
  • CNS Lymphoma Diagnosis and Treatment
  • Genetic factors in colorectal cancer
  • Pancreatic and Hepatic Oncology Research
  • Acute Lymphoblastic Leukemia research
  • Epigenetics and DNA Methylation
  • CAR-T cell therapy research
  • DNA Repair Mechanisms
  • Cancer Immunotherapy and Biomarkers
  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Research Studies
  • BRCA gene mutations in cancer
  • Sarcoma Diagnosis and Treatment
  • PARP inhibition in cancer therapy
  • RNA modifications and cancer
  • Brain Metastases and Treatment
  • Genomics and Rare Diseases

German Cancer Research Center
2015-2024

Heidelberg University
2015-2024

Deutschen Konsortium für Translationale Krebsforschung
2016-2024

Hopp Children's Cancer Center Heidelberg
2018-2024

National Center for Tumor Diseases
2016-2024

University Hospital Heidelberg
2017-2024

Sabin Vaccine Institute
2023

University of Cincinnati
2023

Dana-Farber Cancer Institute
2023

DKFZ-ZMBH Alliance
2017

Pan-cancer analyses that examine commonalities and differences among various cancer types have emerged as a powerful way to obtain novel insights into biology. Here we present comprehensive analysis of genetic alterations in pan-cancer cohort including 961 tumours from children, adolescents, young adults, comprising 24 distinct molecular cancer. Using standardized workflow, identified marked terms mutation frequency significantly mutated genes comparison previously analysed adult cancers....

10.1038/nature25480 article EN cc-by Nature 2018-02-28

Abstract INFORM is a prospective, multinational registry gathering clinical and molecular data of relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long-term follow-up 519 in whom alterations were evaluated according to predefined seven-scale target prioritization algorithm. Mean turnaround time from sample receipt was 25.4 days. The highest priority level observed 42 (8.1%). Of these, 20 received matched targeted treatment median progression-free...

10.1158/2159-8290.cd-21-0094 article EN cc-by-nc-nd Cancer Discovery 2021-08-09
Josefine Radke Naveed Ishaque Randi Koll Zuguang Gu Elisa Schumann and 95 more Lina Sieverling Sebastian Uhrig Daniel Hübschmann Umut H. Toprak Cristina López Xavier Pastor Hostench Simone Borgoni Dilafruz Juraeva Fabienne Pritsch Nagarajan Paramasivam Gnana Prakash Balasubramanian Matthias Schlesner Shashwat Sahay Marc A. Weniger Debora Pehl Helena Radbruch Anja Osterloh Agnieszka Korfel Martin Misch Julia Onken Katharina Faust Peter Vajkoczy Dag Moskopp Yawen Wang Andreas Jödicke Lorenz Trümper Ioannis Anagnostopoulos Dido Lenze Ralf Küppers Michael Hummel Clemens A. Schmitt Otmar D. Wiestler Stephan Wolf Andreas Unterberg Roland Eils Christel Herold‐Mende Benedikt Brors Reiner Siebert Susanne Wagner Andrea Haake Julia Richter Gesine Richter Roland Eils Chris Lawerenz Roland Eils Jules N. A. Kerssemakers Christina Jaeger-Schmidt Ingrid Scholz Anke Bergmann Christoph Borst Friederike Braulke Birgit Burkhardt Alexander Claviez Martin Dreyling Sonja Eberth Hermann Einsele Norbert Frickhofen Siegfried Haas Martin‐Leo Hansmann Dennis Karsch Nicole Klepl Michael Kneba Jasmin Lisfeld Luisa Mantovani‐Löffler Marius Rohde German Ott Christina Stadler Peter Staib Stephan Stilgenbauer Thorsten Zenz Martin‐Leo Hansmann Dieter Kube Siegfried Haas Wolfram Klapper Ulrike Kostezka Peter Möller Andreas Rosenwald German Ott Monika Szczepanowski Ole Ammerpohl Sietse Aukema Vera Binder Arndt Borkhardt Andrea Haake Jessica I. Hoell Ellen Leich Peter Lichter Cristina López Inga Nagel Jordan Pischimariov Bernhard Radlwimmer Julia Richter Philip Rosenstiel Andreas Rosenwald Markus B. Schilhabel

Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell (DLBCLs) confined to (CNS). Molecular drivers PCNSL have not been fully elucidated. Here, we profile and compare whole-genome transcriptome landscape 51 CNS (CNSL) 39 follicular lymphoma 36 DLBCL cases outside CNS. We find recurrent mutations in JAK-STAT, NFkB, receptor signaling pathways, including hallmark MYD88 L265P (67%) CD79B (63%), CDKN2A deletions (83%). PCNSLs exhibit significantly more focal...

10.1038/s41467-022-30050-y article EN cc-by Nature Communications 2022-05-10

Incomplete understanding of the metastatic process hinders personalized therapy. Here we report most comprehensive whole-genome study colorectal metastases vs. matched primary tumors. 65% somatic mutations originate from a common progenitor, with 15% being tumor- and 19% metastasis-specific, implicating higher mutation rate in metastases. Tumor- metastasis-specific harbor elevated levels BRCAness. We confirm multistage progression new components ARHGEF7/ARHGEF33. Recurrently mutated...

10.1038/s41467-018-07041-z article EN cc-by Nature Communications 2018-11-08

iTHER is a Dutch prospective national precision oncology program aiming to define tumour molecular profiles in children and adolescents with primary very high-risk, relapsed, or refractory paediatric tumours. Between April 2017 2021, 302 samples from 253 patients were included. Comprehensive profiling including low-coverage whole genome sequencing (lcWGS), exome (WES), RNA (RNA-seq), Affymetrix, and/or 850k methylation was successfully performed for 226 at least 20% content. Germline...

10.1016/j.ejca.2022.09.001 article EN cc-by European Journal of Cancer 2022-09-29

Abstract Long-term complications such as radiation-induced second malignancies occur in a subset of patients following radiation-therapy, particularly relevant pediatric due to the long follow-up period case survival. Radiation-induced gliomas (RIGs) have been reported after treatment with cranial irradiation for various primary acute lymphoblastic leukemia (ALL) and medulloblastoma (MB). We perform comprehensive (epi-) genetic expression profiling RIGs arising MB (n = 23) ALL 9). Our study...

10.1038/s41467-021-25708-y article EN cc-by Nature Communications 2021-09-20

Abstract Thrombospondins (TSPs) are multidomain glycoproteins with complex matricellular functions in tissue homeostasis and remodeling. We describe a novel role of TSP as Wnt signaling target the basal eumetazoan Hydra . Proteome analysis identified magnipapillata (HmTSP) major component cnidarian mesoglea. In general, domain organization TSPs is related to pentameric bilaterians, phylogenetic analyses formed separate clade high sequence diversity. HmTSP expression polyps was restricted...

10.1038/s41598-018-30035-2 article EN cc-by Scientific Reports 2018-07-31

O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is a predictive biomarker in glioblastoma patients. Glioblastoma without hypermethylated MGMT largely resistant to treatment with temozolomide. These patients are particular need of new approaches, which offered by biomarker-driven clinical trials targeted drugs based on molecular characterization individual tumors.In preparation for an upcoming study, comprehensive profiling approach was undertaken tissues from 43...

10.1093/neuonc/nox216 article EN Neuro-Oncology 2017-11-08

Abstract Background Pediatric patients with relapsed or refractory disease represent a population desperate medical need. The aim of the INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) program is to translate next generation molecular diagnostics into biomarker driven treatment strategy. consists two major foundations: registry providing screening platform and INFORM2 series phase I/II trials. NivEnt trial aims determine recommended 2 dose (RP2D) combination nivolumab...

10.1186/s12885-020-07008-8 article EN cc-by BMC Cancer 2020-06-05

A hierarchically organized cell compartment drives colorectal cancer (CRC) progression. Genetic barcoding allows monitoring of the clonal output tumorigenic cells without prospective isolation. In this study, we asked whether tumor clone-initiating (TcICs) were genetically heterogeneous and differences in self-renewal activation reflected differential kinetics among individual subclones or functional hierarchies within subclones. Monitoring genomic subclone three patient tumors corresponding...

10.1084/jem.20162017 article EN cc-by-nc-sa The Journal of Experimental Medicine 2017-06-01

Abstract Forkhead box R2 (FOXR2) is a forkhead transcription factor located on the X chromosome whose expression normally restricted to testis. In this study, we performed pan-cancer analysis of FOXR2 activation across more than 10,000 adult and pediatric cancer samples found be aberrantly upregulated in 70% all types 8% individual tumors. The majority tumors (78%) expressed through previously undescribed epigenetic mechanism that involves hypomethylation novel promoter, which was...

10.1158/0008-5472.can-22-0671 article EN cc-by-nc-nd Cancer Research 2022-07-08

LBA10503 Background: Several pediatric precision oncology programs have identified molecular actionable variants. However, the clinical benefit is largely unknown. We here report a target prioritization algorithm and associated outcome. Methods: INFORM prospective, non-interventional, multi-center, multi-national, feasibility registry collecting data. Patients with refractory/relapsed/progressive malignant disease, including primary diagnosis high-risk entities, can be enrolled. Fresh frozen...

10.1200/jco.2020.38.18_suppl.lba10503 article EN Journal of Clinical Oncology 2020-06-01

TPS10065 Background: Immune checkpoint inhibition in children has shown limited success rates until now. This is most likely due to the fact that vast majority of pediatric cancers are so-called immunologic cold tumors, and patients have been enrolled an unselected manner single agent trials. Recently, it class I selective HDAC inhibitor entinostat significant immune enhancing activity vitro vivo. mediated through multiple mechanisms including depletion myeloid-derived suppressor cells,...

10.1200/jco.2019.37.15_suppl.tps10065 article EN Journal of Clinical Oncology 2019-05-20

Abstract Inactivating alterations of tumor suppressor gene TP53 are a hallmark progression in various cancer entities. Unfortunately, inactivation has not yet provided an actionable vulnerability. To investigate distribution, mutational pattern and impact pediatric high-grade gliomas (pedHGG), we investigated 407 pedHGG by analyzing genomic sequencing survival data collected through the INFORM MNP molecular diagnostic pipelines. Nearly half (47%) showed signs inactivation. A second hit...

10.1093/neuonc/noae064.305 article EN cc-by-nc Neuro-Oncology 2024-06-18

High-grade glioma (HGG) of the spinal cord constitutes rare tumors in pediatric population. Knowledge molecular profile this HGG (pedHGG) subgroup is limited and clinical outcome poor. Therefore, aim study to provide more profound investigations characteristics features these tumors. Between January 2015 October 2023, 17 with histology were analyzed by Individualized Therapy For Relapsed Malignancies Childhood (INFORM) precision oncology registry. Comprehensive profiling (including...

10.1093/noajnl/vdae185 article EN cc-by-nc Neuro-Oncology Advances 2024-11-08

Abstract Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell (DLBCLs) confined to (CNS). Despite extensive research, molecular alterations leading PCNSL have not been fully elucidated. In order provide a comprehensive description genomic and transcriptional landscape PCNSL, we here performed whole-genome transcriptome sequencing integrative analysis 51 presenting in CNS, including 42 EBV-negative 6 secondary CNS (SCNSL) 3 EBV+ CNSL matched controls. The...

10.1101/2021.07.30.21261280 preprint EN cc-by-nc medRxiv (Cold Spring Harbor Laboratory) 2021-08-05

10509 Background: Relapses from high-risk tumors pose a major clinical challenge in pediatric oncology. The German INFORM registry (INdividualized therapy FOr Relapsed Malignancies children) addresses this problem using integrated next-generation sequencing to rapidly identify patient-specific therapeutic targets. Methods: Whole-exome, low-coverage whole-genome and RNA is complemented with microarray-based DNA methylation profiling. Identified alterations are discussed prioritized according...

10.1200/jco.2017.35.15_suppl.10509 article EN Journal of Clinical Oncology 2017-05-20
Coming Soon ...